User login
Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).
Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.
Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.
Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2
Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).
Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.
Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.
Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2
Key clinical point: Adherence and persistence to adjuvant hormone therapy was associated with improved survival outcomes in older women with hormone receptor-positive (HR+) breast cancer (BC).
Major finding: The risk for all-cause mortality reduced by 25% in patients with vs without cumulative adherence to hormone therapy (hazard ratio [HR] 0.75; P < .001) and decreased by 11% for every 1-year increase in persistence (HR 0.89; P < .001). Each 1-year increase in persistence to hormone therapy also significantly improved breast cancer-specific mortality (HR 0.63; P < .001).
Study details: Findings are from a retrospective analysis of the Surveillance, Epidemiology, and End Results (SEER) data linked with US Medicare claims that included 25,796 older women with HR+ BC who were ≥66 years old and received adjuvant hormone therapy.
Disclosures: This study was partly supported by a grant from the Lilly Endowment, Inc. The authors declared no conflicts of interest.
Source: Zheng D and Thomas J 3rd. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer. Breast Cancer Res Treat. 2023;201:89-104 (Jun 16). Doi: 10.1007/s10549-023-06992-2